Status:
COMPLETED
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
Lead Sponsor:
University of Kansas
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to see if researchers can detect circulating tumor cells (CTC) and circulating endothelial cells (CEC) in the blood.
Detailed Description
Circulating tumors cells (CTCs) and circulating endothelial cells (CECs) are found in the peripheral blood of most common malignancies and are promising surrogate biomarkers. The CellSearchTM CTC assa...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Any patient with radiographic or histologic evidence of renal cell carcinoma who is scheduled to begin treatment with one of the following antiangiogenic agents: sunitinib, sorafenib, temsirolimus or bevacizumab.
- Patients must be candidates to be treated with one of the above agents but there is no limit on the number of prior therapies (i.e. first line or subsequent treatment setting).
- Patients scheduled to undergo debulking nephrectomy prior to beginning systemic therapy do not require histologic diagnosis prior to baseline testing.
- Must be able and willing to sign informed consent.
- Patients must be 18 years or older.
Exclusion
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01173445
Start Date
July 1 2010
End Date
May 1 2011
Last Update
October 20 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160